Campylobacter jejuni, enterotoxigenic Escherichia coli and Shigella sp. are major causes of bacterial diarrhea worldwide. We explored the feasibility of developing a multi-pathogen conjugate vaccine using Escherichia coli proteins as conjugating partners for Campylobacter jejuni and Shigella polysaccharides. We synthesized three conjugate vaccines in which Campylobacter jejuni capsular polysaccharides and Shigella flexneri lipopolysaccharides (selectively activated by TEMPO-mediated oxidation of primary hydroxyls) were conjugated to recombinant Escherichia coli adhesins based on CFA (CfaEB) and CS6 (CssBA). The vaccines were immunogenic in mice as monovalent, bivalent and trivalent formulations and functional antibodies capable of inducing hemaglutination inhibition of a CFA expressing Escherichia coli strain were induced in all conjugate vaccines containing CfaEB. Recently, the WHO highlighted these conjugate vaccines has a preferred product to combat diarrhea in the developing world.

Anti-diarrheal conjugate vaccines

Fall 2022 abstracts, posters, and presentations will launch in mid-September.

ACS Fall 2022

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.